Morgan Stanley
PCVX icon

Morgan Stanley’s Vaxcyte PCVX Stock Holding History

Morgan Stanley’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$46.4M Buy
797,718
+61,811
+8% +$3.36M ﹤0.01% 2306
2026
Q1 		$42.8M Sell
735,907
-99,480
-12% -$5.4M ﹤0.01% 2264
2025
Q4 		$38.5M Buy
835,387
+50,904
+6% +$2.28M ﹤0.01% 2339
2025
Q3 		$28.3M Sell
784,483
-57,439
-7% -$1.9M ﹤0.01% 2556
2025
Q2 		$27.4M Buy
841,922
+234,971
+39% +$7.7M ﹤0.01% 2495
2025
Q1 		$22.9M Sell
606,951
-86,382
-12% -$6.91M ﹤0.01% 2554
2024
Q4 		$56.8M Sell
693,333
-1,536
-0.2% -$153K ﹤0.01% 1727
2024
Q3 		$79.4M Buy
694,869
+285,177
+70% +$25.7M 0.01% 1415
2024
Q2 		$30.9M Sell
409,692
-80,762
-16% -$5.5M ﹤0.01% 2197
2024
Q1 		$33.5M Sell
490,454
-46,911
-9% -$3.25M ﹤0.01% 2140
2023
Q4 		$33.7M Buy
537,365
+127,815
+31% +$6.64M ﹤0.01% 2132
2023
Q3 		$20.9M Sell
409,550
-15,540
-4% -$767K ﹤0.01% 2410
2023
Q2 		$21.2M Buy
425,090
+254,467
+149% +$12.1M ﹤0.01% 2415
2023
Q1 		$6.39M Buy
170,623
+2,508
+1% +$106K ﹤0.01% 3563
2022
Q4 		$8.06M Buy
168,115
+125,582
+295% +$4.93M ﹤0.01% 3283
2022
Q3 		$1.02M Sell
42,533
-95,138
-69% -$2.41M ﹤0.01% 4865
2022
Q2 		$3M Buy
137,671
+48,740
+55% +$1.13M ﹤0.01% 4212
2022
Q1 		$2.15M Buy
88,931
+31,088
+54% +$679K ﹤0.01% 4470
2021
Q4 		$1.38M Buy
57,843
+19,767
+52% +$460K ﹤0.01% 4857
2021
Q3 		$966K Buy
38,076
+18,200
+92% +$441K ﹤0.01% 5063
2021
Q2 		$449K Buy
19,876
+10,405
+110% +$213K ﹤0.01% 5595
2021
Q1 		$187K Sell
9,471
-4,088
-30% -$103K ﹤0.01% 5693
2020
Q4 		$360K Buy
13,559
+10,600
+358% +$394K ﹤0.01% 5263
2020
Q3 		$146K Buy
2,959
+2,859
+2,859% +$114K ﹤0.01% 5259
2020
Q2 		$3K Buy
+100
New +$3.22K ﹤0.01% 6399

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Morgan Stanley's PCVX Position: Q2 2026 in Review

Morgan Stanley increased its Vaxcyte (PCVX) stake by 8.4% in Q2 2026, buying an estimated $3.36M and bringing the position to 797,718 shares worth $46.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2306.

Morgan Stanley first reported a position in PCVX in Q2 2020 and has held it in 25 quarters since. The position peaked at $79.4M in Q3 2024. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Morgan Stanley held 797,718 shares of Vaxcyte worth $46.4M as of Q2 2026.
  • Morgan Stanley bought 61,811 Vaxcyte shares in Q2 2026, an estimated $3.36M.
  • Vaxcyte made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #2306 holding.
  • Morgan Stanley first reported a position in Vaxcyte in Q2 2020 and has held it in 25 quarters since.
  • Morgan Stanley's Vaxcyte position peaked at $79.4M in Q3 2024.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.